Oscar Health: ACA Chaos, ICHRA Growth, And A Potential 2027 Re-Rating

Impact · against what's priced in

Oscar Health faces a fundamental trade-off between a double-digit drop in ACA enrollment and management's aggressive 2027 profitability targets. The potential for a valuation re-rating depends on whether premium hikes and ICHRA growth can successfully neutralize the subsidy-driven volume loss.

OSCR+0.40

No priced-in read yet

In context

Management's target of $2.25 EPS and a 5% operating margin by 2027 suggests a significant undervaluation at current levels, though this is tempered by an expected 10–20% decline in ACA enrollment.

Read from the article alone

• OSCRNew
• revenue growth
• valuation
• aca
• eps
• health insurance
• ichra
• subsidies

Top 1 mover · tap to explore